DOCSLIB.ORG

Distribution of Choline Acetylase and Cholin- Esterase and the Action of Cholinergic Drugs on the Cat Vestibular System

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Distribution of Choline Acetylase and Cholin- Esterase and the Action of Cholinergic Drugs on the Cat Vestibular System Equilibrium Res Suppl. 3, 1972 DISTRIBUTION OF CHOLINE ACETYLASE AND CHOLIN- ESTERASE AND THE ACTION OF CHOLINERGIC DRUGS ON THE CAT VESTIBULAR SYSTEM IZURU MATSUOKA INTRODUCTION It is well known that anticholinergic drugs are useful antimotion remedies. There- fore, it is pertinent to determine the role of cholinergic mechanisms in vestibular function. The known histochernical localization of acetylcholinesterase (AChE) in the cat nucleus vestibularis is complex. AChE is high in the superior and lateral nuclei, but low in the medial and inferior portions. In nucleus vestibularis lateralis (NVL) the cell bodies of Deiters' giant neurons contain almost all of the AChE. Shute and Lewis and Ross, have also shown AChE in the vestibular ganglion of Scarpa. Steiner and Weber and Yamamoto have reported that NVL neurons activated by vestibular stimulation were also excited by the iontophoretic application of acetylcholine (ACh). Further neurophar- macological investigations on the cholinergic mechanisms in the vestibular system are obviously needed. The present manuscript describes our studies on the gross distribution of choline ace- tylase (ChAc), AChE, cholinesterase (ChE), and total cholinesterase in the cat vestibular nerve and nucleus vestibularis lateralis (NVL). In addition, spontaneous unitary dis- charges were recorded in NVL neurons as well as field potentials during vestibular nerve stimulation before and after various cholinergic agonists and antagonists. METHODS Neurochemical analysis Eight adult cats of either sex were used. After 30 mg/kg i.v. of pentobarbital sodium, each animal was placed in a stereotaxic instrument. In order to locate NVL, a small elec- trode was inserted into the right side of the nucleus and fixed to the cranium with dental cement. The right vestibular nerve and brain stem were exposed under microscopic sur- gery using a Zeiss microscope (X6-X40). The vestibular nerve including Scarpa's ganglion and NVL was dissected out for chemical assay. ChAc was assayed radiochemically using a modification of the method of Schrier and Schuster29 and McCaman and Hunt". Total ChE, AChE and ChE were assayed radiochemically using the method of Siakatos et al.". Neuropharmacological studies Thirty-nine normal adult cats of either sex, weighing 2.5 to 4.0 kg, were used. All surgery was performed under diethyl ether-oxygen anesthesia. The trachea, femoral artery Department of Otolaryngology, Faculty of Medicine, University of Kyoto, Kyoto Equilibrium Res Suppl. 3 78 I. MATSUOKA and vein were cannulated. About 8 mm in diameter of the mucous membrane of the middle ear cavity was removed through an approach via the right tympanic bulla. A small concentric bipolar steel electrode was inserted through the round window according to the method of Fredrickson et al.. Another electrode was stereotaxically inserted through the cerebellum into the reticular formation (RF). The recording microelectrodes were gold tipped stainless steel and tungsten wires. Their electrical resistance was bet- ween 0.75 to 10.0 Mƒ¶. The recording electrode was inserted into the right vestibular nucleus, primarily NVL, with the aid of a stereotaxic brain atlas. The microelect- rode was connected through a cathode follower to a Grass P-5 amplifier and the potentials displ;iyed on a Tektronix dual beam oscilloscope. An amplitude discriminator was used to convert the action potentials into a pulse of constant amplitude and duration (TMC, Fig.1. Evoked potential responses of nucleus vestibularis lateralis to ipsilateral vestibular nerve stimulation. Evoked potentials at varying depths in NVL are illustrated. Note that following the stimulus artifact, prominent N1, N2, and N3 waves are re- corded at especially positions 3 through 7 in this nucleus. Note that the voked potential of N, wave has two peaks at position 6. Time base and voltage calibrations are as shown in this and subsequent figures. Equilibrium Res Suppl. 3 CHOLINERGIC MECHANISMS IN THE VESTIBULAR SYSTEM 79 Model 605, 606). This was fed into a CAT 400B computer and data printer (Model 500A) which yielded on-line poststimulus time histograms of single unit activity. In each recording thirty sweeps following stimulation or spontaneous unit activity were summed on the computer. All data displayed on the oscilloscope were photogra- phed on Kodak plus x film using a Grass recording camera. In some cases, the data from the computer were also displayed on a dual beam oscilloscope and recorded on Po- laroid film. After all operative procedures were completed, the animal was locally anesthetized at all wound edges with 0.5% lidocaine and then immobilized with decamethonium (1.0 mg/kg/hr i.v.). Artificial respiration was maintained immediately after injection of deca- methonium. Body temperature was kept at 36•‹ to 38•Ž by means of an automatic heat- ing pad (German Rupp Industry Inc., Model K-1-3). Under these conditions, the mean •} S.E. values of 5 animals' arterial blood of pH, pO, and pCO, were as follows: pH 7.37 •} 0.01, pO2=105.0•}5.7 mmHg, and pCO2=39.0•}6.0 mmHg. These values were almost the same as normal control animals. The arterial blood pressure was recorded by means of a strain gauge from the femoral artery. The right vestibular nerve and the RF were stimulated with a square wave pulse, 0.05 msec and 0.1 msec in width, delivered from a Grass S-8 stimulator. The intensity of stimuli ranged from 1.0 to 5.0 V. Single shock stimuli were usually used, but in some cases pulse trains (50, 150, and 250 Hz, 40 msec train duration and 0.1 msec pulse width) were applied. At the end of each experiment, a 22.5 V dc was applied to the microelectrode so that the site of recording could be confirmed histologically (see Fig.1). RESULTS Cholinergic neurochemistry of the vestibular system As shown in Table 1, the content of ChAc, AChE, ChE and total ChE was higher in NVL than in the vestibular nerve including Scarpa's ganglion. Field potentials in NVL to electrical stimulation of the ipsilateral vestibular nerve Field potentials evoked to vestibular nerve stimulation were classified as N1, N2 and Table 1. Cholinergic neurochemistry of the cat vestibular axon and necleus vestibularis lateralis ChAc is expressed as mean uMol ACh/g/hr•}S.E. AChE was massured using 14C-labelled methacholine, ChE using 14C-butyrylcholine and total ChE using "C-ACh as substrates and expressed as mean uMol/g/hr. Protein is expressed as mg/ml of homogenate. Equilibrium Res Suppl. 3 80 I. MATSUOKA N3 waves. These potentials were almost the same as the P, N, and N2 waves of Shimazu and Precht25.The N,-wave was a small negative and sometimes positive potential. The N2-wave was a large sharp negative potential and the N3-wave was a wide negative po- tential. The means•}S.E. of the latency on these three waves for 7 animals were N1= 0.50•}0.03, N2=1.09•}0.03, and N3=2.43•}0.21 msec. These values were almost the same as Shimazu's. When the microelectrode was inserted into NVL, a characteristic field potential was evoked by single shocks to the vestibular nerve. The typical response was always elicited in the middle portion of NVL. The N2-wave sometimes had two or three peaks. This indicates that there are different conducting axons in the peripheral vestibular nerve. The alterations in the N,- and N2-waves during different placements of the microelectrode from a dorsal to a ventral trajectory are shown in Fig. 1. The po- tentials are helpful for locating single neuronal responses to specific portions of NVL. The mean amplitudes•}S.E. of these waves in seven animals are as follows: N,=96.7•} 10.7, N2=176.3•}14.5, and N3=123.4•}17.5ƒÊV, as illustrated in the bar graph in Fig. 2. Effects of cholinergic agonists The mean amplitude of the N1-wave was reduced slightly to 73.5 •} 10.5ƒÊV 2 min. after administration of nicotine (25ƒÊg/kg i.v.), but this was not statistically significant. The mean amplitude of the N2-wave was reduced to 101.2•}36.1 pV (P<0.01) while the am- plitude of the N3-wave did not change. Five minutes after administration of physostig- Fig.2. Effects of various cholinergic drugs on the amplitude of evoked nucleus vestibularis lateralis potentials elicited with single shocks to the ipsilateral vestibular nerve. Each bar height represents the mean amplitude of a specific wave as designated. Note the dramatic effects of physostigmine in facilitating the N-2wave as well as scopolamine in reducing it. This wave was reduced following nicotine. All responses were measured 5 minutes after drug administration except after nicotine, which was measured 2 minutes after injection.*= P<.05, **=P<.01, ***=P<.001. Equilibrium Res Suppl. 3 CHOLINERGIC MECHANISMS IN THE VESTIBULAR SYSTEM 81 mine (25ƒÊg/kg i.v.), the mean amplitude of the N2-wave increased to 315.0±29.8 pV (P< 0.001). However, the N, and N3-waves did not change (Fig. 2). The accumulative dose response curve of physostigmine is shown in Fig. 3. The N,-wave slightly increased with doses of 25 and 50 ug/kg i.v., but this was not statistically significant. The N2-wave was markably enhanced even in small doses (5ƒÊg/kg i.v.). The N3 wave did not change at all. The optimal dose of physostigmine which facilitated the N2-wave was 25 pg/kg i.v. Larger doses caused a slight reduction. Effects of cholinergic antagonists As described above, the amplitude of the N2-wave was enhanced by physostigmine in doses of 25,ag/kg i.v. This enhancement was reduced by scopolamine in doses of 0.5 mg/kg i.v. In this dose scopolamine did not reduce the N, and N,-waves.
Load more

Recommended publications
  • Effects of the Nicotinic Agonist Varenicline, Nicotinic Antagonist R-Bpidi, and DAT Inhibitor R-Modafinil on Co-Use of Ethanol and Nicotine in Female P Rats
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Psychopharmacology Manuscript Author (Berl) Manuscript Author . Author manuscript; available in PMC 2019 May 01. Published in final edited form as: Psychopharmacology (Berl). 2018 May ; 235(5): 1439–1453. doi:10.1007/s00213-018-4853-4. Effects of the nicotinic agonist varenicline, nicotinic antagonist r-bPiDI, and DAT inhibitor R-modafinil on co-use of ethanol and nicotine in female P rats. Sarah E. Maggio1, Meredith A. Saunders1, Thomas A. Baxter1, Kimberly Nixon2, Mark A. Prendergast1, Guangrong Zheng3, Peter Crooks3, Linda P. Dwoskin2, Rachel D. Slack4, Amy H. Newman4, Richard L. Bell5, and Michael T. Bardo1 1Department of Psychology, University of Kentucky, Lexington, KY 40536, USA. 2Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536, USA. 3Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas, Little Rock, AR 72205, USA. 4Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse- Intramural Research Program, National Institutes of Health, Baltimore, Maryland 21224, USA. 5Department of Psychiatry, Institute of Psychiatric Research, Indiana University School of Medicine, Indianapolis, IN 46202, USA. Abstract Rationale: Co-users of alcohol and nicotine are the largest group of polysubstance users worldwide. Commonalities in mechanisms of action for ethanol (EtOH) and nicotine proposes the possibility of developing a single pharmacotherapeutic to treat co-use. Objectives: Toward developing a preclinical model of co-use, female alcohol-preferring (P) rats were trained for voluntary EtOH drinking and i.v. nicotine self-administration in three phases: (1) EtOH alone (0 vs. 15%, 2-bottle choice); (2) nicotine alone (0.03 mg/kg/infusion, active vs.
    [Show full text]
  • Expression of Multiple Populations of Nicotinic Acetylcholine
    EXPRESSION OF MULTIPLE POPULATIONS OF NICOTINIC ACETYLCHOLINE RECEPTORS IN BOVINE ADRENAL CHROMAFFIN CELLS DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy in the Graduate School of The Ohio State University By Bryan W. Wenger, B.A. The Ohio State University 2003 Dissertation Committee: Approved by: Professor Dennis B. McKay, Advisor Professor R. Thomas Boyd ________________________ Advisor Professor Popat N. Patil College of Pharmacy Professor Lane Wallace, Ph.D. ABSTRACT The importance of the role of nAChRs in physiological and pathological states is becoming increasingly clear. It is apparent that there are multitudes of nAChR subtypes with different expression patterns, pharmacologies and functions that may be important in various disease states. Therefore, a greater understanding of nAChR subtypes is essential for potential pharmacological intervention in nAChR systems. Bovine adrenal chromaffin cells are a primary culture of a neuronal type cell that express ganglionic types of nAChRs whose activation can be related to a functional response. While much is known about the outcome of functional activation of adrenal nAChRs, little work has been done in characterizing populations of nAChRs in adrenal chromaffin cells. These studies characterize the pharmacology and regulation of populations of nAChRs found in bovine adrenal chromaffin cells. The primary findings of this research include 1) the characterization of an irreversible antagonist of adrenal nAChRs, 2) the discovery of
    [Show full text]
  • Muscle Relaxants Physiologic and Pharmacologic Aspects
    K. Fukushima • R. Ochiai (Eds.) Muscle Relaxants Physiologic and Pharmacologic Aspects With 125 Figures Springer Contents Preface V List of Contributors XVII 1. History of Muscle Relaxants Some Early Approaches to Relaxation in the United Kingdom J.P. Payne 3 The Final Steps Leading to the Anesthetic Use of Muscle Relaxants F.F. Foldes 8 History of Muscle Relaxants in Japan K. Iwatsuki 13 2. The Neuromuscular Junctions - Update Mechanisms of Action of Reversal Agents W.C. Bowman 19 Nicotinic Receptors F.G. Standaert 31 The Neuromuscular Junction—Basic Receptor Pharmacology J.A. Jeevendra Martyn 37 Muscle Contraction and Calcium Ion M. Endo 48 3. Current Basic Experimental Works Related to Neuromuscular Blockade in Present and Future Prejunctional Actions of Neuromuscular Blocking Drugs I.G. Marshall, C. Prior, J. Dempster, and L. Tian 51 VII VIII Approaches to Short-Acting Neuromuscular Blocking Agents J.B. Stenlake 62 Effects Other than Relaxation of Non-Depolarizing Muscle Relaxants E.S. Vizi 67 Regulation of Innervation-Related Properties of Cultured Skeletal Muscle Cells by Transmitter and Co-Transmitters R.H. Henning 82 4. Current Clinical Experimental Works Related to Neuromuscular Blockade in Present and Future Where Should Experimental Works Be Conducted? R.D. Miller 93 Muscle Relaxants in the Intensive Care Unit ! J.E. Caldwell 95 New Relaxants in the Operating Room R.K. Mirakhur 105 Kinetic-Dynamic Modelling of Neuromuscular Blockade C. Shanks Ill 5. Basic Aspects of Neuromuscular Junction Physiology of the Neuromuscular Junction W.C. Bowman 117 Properties of <x7-Containing Acetylcholine Receptors and Their Expression in Both Neurons and Muscle D.K.
    [Show full text]
  • Muscle Relaxants Femoral Arteriography.,,>
    IN THIS ISSUE: , .:t.i ". Muscle Relaxants fI, \'.' \., Femoral ArteriographY.,,> University of Minnesota Medical Bulletin Editor ROBERT B. HOWARD, M.D. Associate Editors RAY M. AMBERG GILBERT S. CAMPBELL, M.D. ELLIS S. BENSON, MD. BYRON B. COCHRANE, M.D. E. B. BROWN, PhD. RICHARD T. SMITH, M.D. WESLEY W. SPINK, MD. University of Minnesota Medical School J. 1. MORRILL, President, University of Minnesota HAROLD S. DIEHL, MD., Dean, College of Medical SciencBs WILLIAM F. MALONEY, M.D., Assistant Dean N. 1. GAULT, JR., MD., Assistant Dean University Hospitals RAY M. AMBERG, Director Minnesota Medical Foundation WESLEY W. SPINK, M.D., President R. S. YLVISAKER, MD., Vice-President ROBERT B. HOWARD, M.D., Secretary-Treasurer Minnesota Medical Alumni Association BYRON B. COCHRANE, M.D., President VIRGIL J. P. LUNDQUIST, M.D., First Vice-President SHELDON M. LAGAARD, MD., Second Vice-President LEONARD A. BOROWICZ, M.D., Secretary JAMES C. MANKEY, M.D., Treasurer UNIVERSITY OF MINNESOTA Medical Bulletin OFFICIAL PUBLICATION OF THE UNIVERSITY OF MINNESOTA HOSPITALS, MINNE· SOTA MEDICAL FOUNDATION, AND MINNESOTA MEDICAL ALUMNI ASSOCIATION VOLUME XXVIII December 1, 1956 NUMBER 4 CONTENTS STAFF MEETING REPORTS Current Status of Muscle Relaxants BY J. Albert Jackson, MD., J. H. Matthews, M.D., J. J. Buckley, M.D., D.S.P. Weatherhead, M.D., AND F. H. Van Bergen, M.D. 114 Small Vessel Changes in Femoral Arteriography BY Alexander R. Margulis, M.D. AND T. O. Murphy, MD.__ 123 EDITORIALS .. - -. - ---__ __ _ 132 MEDICAL SCHOOL ACTIVITIES ----------- 133 POSTGRADUATE EDUCATION - 135 COMING EVENTS 136 PIIb1ished semi.monthly from October 15 to JUDe 15 at Minneapolis, Minnesota.
    [Show full text]
  • Pharmacological Studies on Pupillary Reflex Dilatation
    PHARMACOLOGICAL STUDIES ON PUPILLARY REFLEX DILATATION SHINJI OONO Departmentof Pharmacology,Faculty of Medicine,Kyushu University, Fukuoka Received for publication September 20, 1964 Concerning the role of sympathetic and parasympathetic mechanisms in reflex dilatation of the pupil elicited by painful stimuli, there have long been many argu ments. One group of authors, for example, Bechterew (1) and Braunstein (2) concluded that the pupillary dilatation resulting from painful stimuli was caused solely by inhibi tion of the third cranial nerve activity. Another group of investigators, for example, Lieben and Kahn (3), Bain, Irving and McSwiney (4), Ury and Gellhorn (5), Ury and Oldberg (6) and Seybold and Moore (7) were of the opinion that parasympathetic in hibition was the principal factor in the reflex dilatation while sympathetic excitation was a negligible one. On the contrary, others, for instance, Luchsinger (8), Anderson (9), and Dechaume (10) claimed that sympathetic excitation was responsible for the pupillary reaction which was absent after cervical sympathectomy. Weinstein and Bender (11) compared the pupillary reflex activity in cats and mon keys. They concluded that a species-difference exists: in both species pupillary dilata tion is accomplished by both parasympathetic inhibitory and sympathetic excitatory mechanism. In the cat, inhibition of the parasympathetic mechanism is predominant while in the monkey excitation of the sympathetic mechanism is of greater importance . Later Lowenstein and Loewenfeld (12) performed more detailed experiments in cats using their own pupillographic instrument; they observed that pupillary reflex dilata tion was mostly due to sympathetic excitation, and was reduced to less than one-fifth of the normal control dilatation after sympathectomy.
    [Show full text]
  • Cognitive, Behavioral, and Physiologic Responses John T
    Combined Nicotinic and Muscarinic Blockade in Elderly Normal Volunteers: Cognitive, Behavioral, and Physiologic Responses John T. Little, M.D., Douglas N. Johnson, Ph.D., Marcia Minichiello, M.A., Herb Weingartner, Ph.D., and Trey Sunderland, M.D. Establishing a pharmacologic model of the memory deficits scopolamine alone. Increased impairment was also seen for of Alzheimer’s disease could be an important tool in the mecamylamine 1 scopolamine condition as compared to understanding how memory fails. We examined the scopolamine alone in selected behavioral ratings. Pupil size combined effects of the muscarinic antagonist scopolamine increased when mecamylamine was added to scopolamine, and the nicotinic antagonist mecamylamine in eight normal while systolic blood pressure and pulse changed in elderly volunteers (age 61.9 6 8.3 yrs, SD). Each received concordance with ganglionic blockade. These data together four separate drug challenges (scopolamine (0.4 mg IV), with previous brain-imaging results suggest that this mecamylamine (0.2 mg/kg up to 15 mg PO), muscarinic–nicotinic drug combination may better model mecamylamine 1 scopolamine, and placebo). There was a Alzheimer’s disease than either drug alone. trend toward increased impairment in explicit memory for [Neuropsychopharmacology 19:60–69, 1998] the mecamylamine 1 scopolamine condition as compared to Published by Elsevier Science Inc. KEY WORDS: Scopolamine; Mecamylamine; Cognitive; al. 1985; Shimohama et al. 1986; Whitehouse and Au Geriatrics; Muscarinic antagonist; Nicotinic antagonist 1986; D’Amato et al. 1987; Zubenko et al. 1988), many cognitive dysfunction modeling studies have focused Given the limited animal models of Alzheimer’s disease on this system (Beatty et al.
    [Show full text]
  • Treating Smoking Dependence in Depressed Alcoholics
    Treating Smoking Dependence in Depressed Alcoholics Nassima Ait-Daoud, M.D.; Wendy J. Lynch, Ph.D.; J. Kim Penberthy, Ph.D.; Alison B. Breland, Ph.D.; Gabrielle R. Marzani-Nissen, M.D.; and Bankole A. Johnson, D.Sc., M.D., Ph.D. Alcoholism and nicotine dependence share many neurobiological underpinnings; the presence of one drug can cause a person to crave the other. Depressive illness can complicate comorbid alcohol and nicotine dependence by exacerbating the negative affect encountered during attempts to abstain from one or both drugs. Given the morbidity and mortality associated with cigarette smoking, it is imperative to identify treatments to promote smoking cessation and address comorbid psychiatric conditions contemporaneously. Pharmacotherapeutic options demonstrating varying degrees of efficacy and promise in preclinical and clinical studies include nicotine replacement therapy (NRT), selective serotonin reuptake inhibitors (SSRIs), bupropion, varenicline, tricyclic antidepressants, and bupropion plus NRT. Topiramate has shown potential for promoting smoking cessation in alcoholics, although its safety in depressed patients has not been fully explored. The efficacy of medications for treating nicotine dependence is generally enhanced by the inclusion of behavioral interventions such as cognitive behavioral therapy. When group cohesion and social support are stressed, success rates increase among depressed smokers undergoing smoking cessation treatment. Additional treatment strategies targeting dually dependent individuals with
    [Show full text]
  • Opioid and Nicotine Use, Dependence, and Recovery: Influences of Sex and Gender
    Opioid and Nicotine: Influences of Sex and Gender Conference Report: Opioid and Nicotine Use, Dependence, and Recovery: Influences of Sex and Gender Authors: Bridget M. Nugent, PhD. Staff Fellow, FDA OWH Emily Ayuso, MS. ORISE Fellow, FDA OWH Rebekah Zinn, PhD. Health Program Coordinator, FDA OWH Erin South, PharmD. Pharmacist, FDA OWH Cora Lee Wetherington, PhD. Women & Sex/Gender Differences Research Coordinator, NIH NIDA Sherry McKee, PhD. Professor, Psychiatry; Director, Yale Behavioral Pharmacology Laboratory Jill Becker, PhD. Biopsychology Area Chair, Patricia Y. Gurin Collegiate Professor of Psychology and Research Professor, Molecular and Behavioral Neuroscience Institute, University of Michigan Hendrée E. Jones, Professor, Department of Obstetrics and Gynecology; Executive Director, Horizons, University of North Carolina at Chapel Hill Marjorie Jenkins, MD, MEdHP, FACP. Director, Medical Initiatives and Scientific Engagement, FDA OWH Acknowledgements: We would like to acknowledge and extend our gratitude to the meeting’s speakers and panel moderators: Mitra Ahadpour, Kelly Barth, Jill Becker, Kathleen Brady, Tony Campbell, Marilyn Carroll, Janine Clayton, Wilson Compton, Terri Cornelison, Teresa Franklin, Maciej Goniewcz, Shelly Greenfield, Gioia Guerrieri, Scott Gottlieb, Marsha Henderson, RADM Denise Hinton, Marjorie Jenkins, Hendrée Jones, Brian King, George Koob, Christine Lee, Sherry McKee, Tamra Meyer, Jeffery Mogil, Ann Murphy, Christine Nguyen, Cheryl Oncken, Kenneth Perkins, Yvonne Prutzman, Mehmet Sofuoglu, Jack Stein, Michelle Tarver, Martin Teicher, Mishka Terplan, RADM Sylvia Trent-Adams, Rita Valentino, Brenna VanFrank, Nora Volkow, Cora Lee Wetherington, Scott Winiecki, Mitch Zeller. We would also like to thank those who helped us plan this program. Our Executive Steering Committee included Ami Bahde, Carolyn Dresler, Celia Winchell, Cora Lee Wetherington, Jessica Tytel, Marjorie Jenkins, Pamela Scott, Rita Valentino, Tamra Meyer, and Terri Cornelison.
    [Show full text]
  • Neuronal Nicotinic Receptors
    NEURONAL NICOTINIC RECEPTORS Dr Christopher G V Sharples and preparations lend themselves to physiological and pharmacological investigations, and there followed a Professor Susan Wonnacott period of intense study of the properties of nAChR- mediating transmission at these sites. nAChRs at the Department of Biology and Biochemistry, muscle endplate and in sympathetic ganglia could be University of Bath, Bath BA2 7AY, UK distinguished by their respective preferences for C10 and C6 polymethylene bistrimethylammonium Susan Wonnacott is Professor of compounds, notably decamethonium and Neuroscience and Christopher Sharples is a hexamethonium,5 providing the first hint of diversity post-doctoral research officer within the among nAChRs. Department of Biology and Biochemistry at Biochemical approaches to elucidate the structure the University of Bath. Their research and function of the nAChR protein in the 1970’s were focuses on understanding the molecular and facilitated by the abundance of nicotinic synapses cellular events underlying the effects of akin to the muscle endplate, in electric organs of the acute and chronic nicotinic receptor electric ray,Torpedo , and eel, Electrophorus . High stimulation. This is with the goal of affinity snakea -toxins, principallyaa -bungarotoxin ( - Bgt), enabled the nAChR protein to be purified, and elucidating the structure, function and subsequently resolved into 4 different subunits regulation of neuronal nicotinic receptors. designateda ,bg , and d .6 An additional subunit, e , was subsequently identified in adult muscle. In the early 1980’s, these subunits were cloned and sequenced, The nicotinic acetylcholine receptor (nAChR) arguably and the era of the molecular analysis of the nAChR has the longest history of experimental study of any commenced.
    [Show full text]
  • 2018 Medicines in Development for Skin Diseases
    2018 Medicines in Development for Skin Diseases Acne Drug Name Sponsor Indication Development Phase ADPS topical Taro Pharmaceuticals USA acne vulgaris Phase II completed Hawthorne, NY www.taro.com AOB101 AOBiome acne vulgaris Phase II (topical ammonia oxidizing bacteria) Cambridge, MA www.aobiome.com ASC-J9 AndroScience acne vulgaris Phase II (androgen receptor degradation Solana Beach, CA www.androscience.com enhancer) BLI1100 Braintree Laboratories acne vulgaris Phase II completed Braintree, MA www.braintreelabs.com BPX-01 BioPharmX acne vulgaris Phase II (minocycline topical) Menlo Park, CA www.biopharmx.com BTX1503 Botanix Pharmaceuticals moderate to severe acne vulgaris Phase II (cannabidiol) Plymouth Meeting, PA www.botanixpharma.com CJM112 Novartis Pharmaceuticals acne vulgaris Phase II (IL-17A protein inhibitor) East Hanover, NJ www.novartis.com clascoterone Cassiopea acne vulgaris Phase III (androgen receptor antagonist) Lainate, Italy www.cassiopea.com Medicines in Development: Skin Diseases ǀ 2018 Update 1 Acne Drug Name Sponsor Indication Development Phase CLS001 Cutanea acne vulgaris Phase II (omiganan) Wayne, PA www.cutanea.com DFD-03 Promius Pharma acne vulgaris Phase III (tazarotene topical) Princeton, NJ www.promiuspharma.com DMT310 Dermata Therapeutics moderate to severe acne vulgaris Phase II (freshwater sponge-derived) San Diego, CA www.dermatarx.com finasteride Elorac severe nodulocystic acne Phase II (cholestenone 5-alpha Vernon Hills, IL www.eloracpharma.com reductase inhibitor) FMX101 Foamix moderate to severe
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Clinical Pharmacokinetics of Muscle Relaxants
    i ,I .. / ,""- Clinical Pharmacokinetics 2: 330-343 (1977) © ADIS Press 1977 Clinical Pharmacokinetics of Muscle Relaxants L.B. Wingard and DR. Cook Departments of Pharmacology and Anesthesiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania SUl1lmary Muscle relaxants are commonly used as an adjunct to general anaesthesia and to facilitate ventilator care in the intensive care unit. The muscle relaxants are unique in that the degree of neurol1luscular blockade can be directly measured. Thus, for some of the muscle relaxants it is possible to correlate the degree of neuromuscular blockade with the plasma concentration of drug. This quantilalive pllGrmacokinelic approach has been applied primarily to d­ tubocurarine and to a lesser extent to suxamethonium (succinylcholine), gallamine and pan­ curoniul1l. The pharl1lacokinetic information for the other relaxants is mostly descriptive and incomplete. The variation in drug concentration over time is in.fluenced by the distribution, metabolism and excretion of drug. Metabolism by plasma cholinesterase plays a maJor role in the termina­ tion (~f action of suxamethonium. Although pancuronium is partly metabolised its major metabolites have moderate pharmacological activity. The other relaxants are excreted through the kidney. For gallamine and dimethyl-tubocurarine, renal excretion appears to be the only means qf eliinination. However, biliary excretion probably provides an alternative route of elimination for d-tubocurarine and pancuronium. In patients with impaired renal function the duration qf neuromusClilar blockade may be markedly prolonged following standard doses of gallamine or dimethyl-tubocurarine, may be slightly prolonged following standard doses of pancumnium, and is near normal following standard doses qf d-tubocurarine. Following large or repeated doses q(pancuronium or d-tubocurarine, the duration q{ neuromuscular blockade may be markedly prolonged.
    [Show full text]